Aadi Bioscience, Inc. (NASDAQ:AADI - Get Free Report) shares were down 16.1% during trading on Monday . The stock traded as low as $3.00 and last traded at $3.02. Approximately 441,737 shares traded hands during trading, an increase of 8% from the average daily volume of 410,748 shares. The stock had previously closed at $3.60.
Aadi Bioscience Price Performance
The firm has a market capitalization of $73.94 million, a price-to-earnings ratio of -1.32 and a beta of 0.65. The stock has a 50 day moving average price of $2.61 and a two-hundred day moving average price of $2.03.
Aadi Bioscience (NASDAQ:AADI - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.46) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.46). The business had revenue of $7.21 million for the quarter, compared to analysts' expectations of $6.55 million. Aadi Bioscience had a negative net margin of 246.06% and a negative return on equity of 71.87%. During the same quarter in the prior year, the company earned ($0.60) earnings per share. As a group, research analysts expect that Aadi Bioscience, Inc. will post -1.78 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Aadi Bioscience
Several institutional investors have recently modified their holdings of the business. XTX Topco Ltd acquired a new stake in shares of Aadi Bioscience in the 3rd quarter valued at $32,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Aadi Bioscience in the second quarter valued at $37,000. Finally, BML Capital Management LLC acquired a new stake in Aadi Bioscience in the third quarter valued at $4,120,000. Institutional investors and hedge funds own 52.08% of the company's stock.
About Aadi Bioscience
(
Get Free Report)
Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.
Featured Articles
Before you consider Aadi Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aadi Bioscience wasn't on the list.
While Aadi Bioscience currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
